Pharmacokinetics News and Research

RSS

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.

27 Sep 2010

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Enobia Pharma today announced positive results for its Phase II juvenile clinical trial of ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy intended for the treatment of hypophosphatasia (HPP). Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

24 Sep 2010

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced miravirsen (SPC3649), the first microRNA-targeted drug to enter clinical trials, into Phase 2 studies to assess the safety and tolerability of the drug in treatment-naive patients infected with the Hepatitis C virus.

22 Sep 2010

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

Celsion Corporation announced today that an abstract on its Phase I/II DIGNITY trial of ThermoDox in Recurrent Chest Wall Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. The abstract will provide updated clinical results, as well as the rationale and design of the DIGNITY study, which is evaluating ThermoDox in combination with microwave hyperthermia in women with RCW Breast Cancer.

22 Sep 2010

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

Boston Scientific Corporation today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent. The results provided 30-day and nine-month clinical outcomes and nine-month quantitative coronary angiography (QCA) and intravascular ultrasound (IVUS) data supporting the safety and efficacy of the PROMUS Element Stent.

22 Sep 2010

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

The University of Maryland School of Pharmacy has received a prestigious $3.7 million grant to develop a drug to treat cocaine addiction based on an active ingredient found in some Chinese prescription medicines.

21 Sep 2010

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 3, a Phase II clinical program evaluating the effect of repeated cycles of the company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non-Responders (INR) after at least 24 months of highly active anti-retroviral therapy (HAART).

21 Sep 2010

CEDRA is renamed as Worldwide Clinical Trials Drug Development Solutions

For over 20 years, CEDRA Corporation, a division of Worldwide Clinical Trials, has been an industry leader in providing Bioanalytical Sciences and Phase I-IIb Clinical Research Services. Operating as a division of Worldwide Clinical Trials over the past three years, today, CEDRA Corporation announces its new company name, Worldwide Clinical Trials Drug Development Solutions.

20 Sep 2010

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

Aradigm Corporation today announced it is presenting data on September 22, 2010, from its Phase 1 studies at the ERS Annual Congress in Barcelona, Spain. The podium presentation elaborates on the pharmacokinetic parameters of ciprofloxacin in the blood and sputum samples that were observed in the healthy volunteers and non-cystic fibrosis bronchiectasis (BE) patients.

17 Sep 2010

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, today presented five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

16 Sep 2010

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

16 Sep 2010

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

A new clinical trial supports the benefits to people with osteoarthritis who used a unique extract of turmeric. Scientists in Italy have studied the pain-relief, increased flexibility, and other effects of a special, patented extract of the roots of turmeric, the flavorful spice that has been used for centuries as a traditional remedy. Turmeric formulations have shown a wide range of safety and significant scientific and clinical benefits in recent animal research and human clinical trials.

16 Sep 2010

ESMO honors three eminent cancer specialists for their contribution towards medical research

The European Society for Medical Oncology (ESMO) honors three eminent cancer specialists for their contribution to the advancement of medical research. The awards will be presented to Hilary Calvert, Alberto Costa and Bengt Glimelius at the 35th ESMO Congress, to take place from 8-12 October in Milan, Italy.

16 Sep 2010

ESMO honors eminent cancer specialists

15 Sep 2010

COTI selected for Canadian life sciences partnering mission

Critical Outcome Technologies Inc. announced today that the Company was selected by the Consulate General of Canada and BIOTECanada to attend a life sciences partnering mission in Boston, MA. This initiative is being held in conjunction with the BioPharm America conference taking place September 15-17, 2010.

15 Sep 2010

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Harbor BioSciences, Inc. a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today released new positive data from its ongoing Phase I/IIa clinical trial with Apoptone(HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

15 Sep 2010

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Elsevier today announces that it has significantly increased its service offering to pharmaceutical R&D professionals with the launch of a new Pharmacokinetics Module of PharmaPendium-, the online resource for authoritative drug development data.

15 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Pharmacokinetics News and Research

Further Reading

KAI Pharmaceuticals enrolls patients in Phase 1b study of KAI-4169 for treatment of SHPT

Enobia announces positive results from ENB-0040 Phase II juvenile clinical trial for hypophosphatasia

Santaris Pharma paves way to conduct clinical trial of miravirsen in patients with HVC

Phase I/II DIGNITY trial abstract of ThermoDox accepted for poster session at 2010 Breast Cancer Symposium

Boston Scientific reports positive data from PLATINUM Element Stent quantitative coronary angiography study

NIDA awards 5-year, $3.7M research grant for development of drug to treat cocaine addiction

Cytheris commences enrollment in CYT107 recombinant human Interleukin-7 clinical trial for HIV

CEDRA is renamed as Worldwide Clinical Trials Drug Development Solutions

Aradigm to present Phase 1 studies of inhaled liposomal ciprofloxacin at 2010 ERS Congress

PolyMedix presents defensin mimetic antibiotics data at ICAAC Conference

Chimerix presents promising clinical data for CMX001 in late-breaker poster session at 50th ICAAC

New clinical trial supports benefits of turmeric extract to people with osteoarthritis

ESMO honors three eminent cancer specialists for their contribution towards medical research

ESMO honors eminent cancer specialists

COTI selected for Canadian life sciences partnering mission

Harbor BioSciences releases Apoptone clinical trial data for castration resistant prostate cancer

Elsevier launches new Pharmacokinetics Module of PharmaPendium

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Industry Focus - Biopharma eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News